Cat. No.: HY-107260

Lucidenic acid D

(Synonyms: Lucidenic acid D2)

Customer Review

Based on 1 Customer Validation

Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention.

For research use only. We do not sell to patients.

Purity: 99.41%
CAS No.: 98665-16-8
Formula: C₂₉H₃₈O₈
Molecular Weight:514.61

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lucidenic acid D Chemical Structure

CAS No.: 98665-16-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

All NO Synthase Isoforms :

All COX Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Raji	IC₅₀	287 molar ratio Compound: 5a	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed per 32 pmol TPA by immunofluorescence technique Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed per 32 pmol TPA by immunofluorescence technique	[PMID: 14695801]

In Vitro

Lucidenic acid D (as methyl lucidenate D) is a new highly oxidized lanostane-type triterpenoid isolated from Ganoderma lucidum gills, with its structure elucidated using spectral evidence including mass spectrometry, ¹H-NMR, and ¹³C-NMR^[1].
Lucidenic acid D inhibits Epstein-Barr virus early antigen activation in Raji cells^[2].
Lucidenic acid D (10, 50 μg/mL; 30 min) does not alter LPS-induced p38 or JNK phosphorylation in THP-1 cells^[3].
Lucidenic acid D (50 μg/mL; 4 h) does not significantly enhance LPS-induced TNFα mRNA expression in THP-1 cells^[3].
Lucidenic acid D₂ (10-1000 mol ratio/TPA; 48 h) potently inhibits EBV-EA activation in Raji cells, with an IC₅₀ of 287 mol ratio/TPA, and maintains 70% cell viability at the highest tested concentration^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[4]

Cell Line:

Raji cells (EBV genome-carrying human lymphoblastoid cells)
Concentration:

10-1000 mol ratio/TPA
Incubation Time:

48 h
Result:

Inhibited EBV-EA induction by 98% at 1000 mol ratio/TPA, with 70% Raji cell viability.
Inhibited EBV-EA induction by 73.9% at 500 mol ratio/TPA.
Inhibited EBV-EA induction by 26.2% at 100 mol ratio/TPA.
Inhibited EBV-EA induction by 3.9% at 10 mol ratio/TPA.
Reached an IC₅₀ of 287 mol ratio/TPA for inhibition of EBV-EA induction.

Chemical Information

CAS No. 98665-16-8
Appearance Solid
Molecular Weight 514.61
Formula C₂₉H₃₈O₈
Color Off-white to yellow
SMILES

C[C@@]([C@@H]1OC(C)=O)([C@@](C2)([H])[C@H](C)CCC(O)=O)[C@](C(C(C[C@@]3([H])C4(C)C)=O)=C([C@]3(CCC4=O)C)C1=O)(C2=O)C
Synonyms

Lucidenic acid D2
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tohru Kikuchi, et al. GANODERIC ACID D, E, F, AND H AND LUCIDENIC ACID D, E, AND F, NEW TRITERPENOIDS FROM GANODERMA LUCIDUM. Chem Pharm Bull. 1985, 33 (6): 2624-2627.

[2]. Zheng C, et al. A Review on the Sources, Structures, and Pharmacological Activities of Lucidenic Acids. Molecules. 2023;28(4):1756. Published 2023 Feb 12. [Content Brief]

[3]. Watanabe K, et al. Lucidenic acids-rich extract from antlered form of Ganoderma lucidum enhances TNFα induction in THP-1 monocytic cells possibly via its modulation of MAP kinases p38 and JNK. Biochem Biophys Res Commun. 2011;408(1):18-24. [Content Brief]

[4]. Iwatsuki K, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. J Nat Prod. 2003;66(12):1582-1585. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Lucidenic acid D

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

All NO Synthase Isoforms

All COX Isoforms